retatrutide triple agonist glp-1 gip glucagon phase 2 obesity is gaining attention in metabolic research for its activity on GIP, GLP-1, and receptors. In this carousel, we summarize recent clinical study findings related to weight management, type When the Breakthrough Obesity G-Agonist

If more than five days have passed, skip the missed dose entirely and resume your regular schedule the following week

This is significant for combination protocols because it suggests that adding cagrilintide to retatrutide may not dramatically increase the gastrointestinal burden, provided the titration is managed correctly

Durability of metabolic effects beyond the phase 2 windows, and outcomes following discontinuation, are questions that longer trials are designed to address

Twenty-four-hour profiles of acylated and total ghrelin: relationship with glucose levels and impact of time of day and sleep

Who is leaning into GLP-1 specifics in 2026

These studies help doctors understand both the benefits and the possible risks over the long term